Literature DB >> 34889854

Clinical, Morphologic, and Molecular Features Associated With Ovarian Metastases From Pattern A Endocervical Adenocarcinomas.

Jacqueline Feinberg1, Anjelica Hodgson2, Nadeem R Abu-Rustum1,3, Kara Long Roche1,3, Kay J Park2.   

Abstract

Ovarian metastases from endocervical adenocarcinomas (EAs) are rare but well-described. Silva Pattern A tumors have been reported to pose essentially no risk of lymph node metastases or recurrence. We describe a cohort of patients with Silva Pattern A EAs with ovarian metastases, as well as involvement of other sites. Eight pattern A EAs with ovarian metastases (4 synchronous, 4 metachronous) were identified from our institution's pathologic archives (2008-2021). Clinicopathologic and molecular features for each case were recorded. All patients were treated by hysterectomy; in each case, the entire tumor was submitted for histologic evaluation. The synchronous metastases were all clinically suspected to be ovarian primary tumors; EAs with metachronous ovarian involvement were confined to the uterus at initial diagnosis, with ovarian metastasis occurring 5 to 171 months after hysterectomy. Morphologically, all tumors were predominantly gland-forming, 5/8 (63%) displayed prominent mucinous differentiation, and 5/8 (63%) involved the corpus. All EAs were either noninvasive (exophytic/papillary/more complex than adenocarcinoma in situ) or showed nondestructive cervical stromal invasion to a depth of 5 mm or less. In the 5 tumors tested by next-generation sequencing, ARID1A, GNAS, and KRAS mutations were detected in 2 (40%), 3 (60%), and 4 (80%) cases, respectively. All 6 patients with follow-up (range, 32 to 181 mo; median, 99.5 mo) had at least 1 recurrence. All but one are without evident disease at last clinical assessment. In an otherwise typical Silva Pattern A EA, corpus involvement, mucinous differentiation, and certain gene mutations may be associated with risk for synchronous or metachronous ovarian metastases.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 34889854      PMCID: PMC8930534          DOI: 10.1097/PAS.0000000000001845

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  35 in total

1.  Should ovaries be removed or not in early-stage cervical adenocarcinoma: a multicenter retrospective study of 105 patients.

Authors:  Jun Hu; Xiaobing Jiao; Zhifeng Yang; Heng Cui; Hongyan Guo; Yumei Wu; Lirong Zhu
Journal:  J Obstet Gynaecol       Date:  2017-06-20       Impact factor: 1.246

2.  Invasive endocervical adenocarcinoma: a new pattern-based classification system with important clinical significance.

Authors:  Andres A Roma; Andrea Diaz De Vivar; Kay J Park; Isabel Alvarado-Cabrero; Golnar Rasty; Jose G Chanona-Vilchis; Yoshiki Mikami; Sung R Hong; Norihiro Teramoto; Rouba Ali-Fehmi; Joanne K L Rutgers; Denise Barbuto; Elvio G Silva
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

3.  Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.

Authors:  Sergio Pecorelli
Journal:  Int J Gynaecol Obstet       Date:  2009-05       Impact factor: 3.561

4.  Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Sandra P D'Angelo; Andre L Moreira; Deborah Kuk; Camelia S Sima; Gregory J Riely; Maria E Arcila; Mark G Kris; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

5.  Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.

Authors:  Anjelica Hodgson; Yutaka Amemiya; Arun Seth; Matthew Cesari; Bojana Djordjevic; Carlos Parra-Herran
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

6.  Ovarian preservation in young patients with stage I cervical adenocarcinoma: a surveillance, epidemiology, and end results study.

Authors:  Jiangtao Lyu; Tingting Sun; Xianjie Tan
Journal:  Int J Gynecol Cancer       Date:  2014-10       Impact factor: 3.437

7.  A comparison of ovarian metastasis between squamous cell carcinoma and adenocarcinoma of the uterine cervix.

Authors:  T Nakanishi; K Wakai; H Ishikawa; A Nawa; Y Suzuki; S Nakamura; K Kuzuya
Journal:  Gynecol Oncol       Date:  2001-09       Impact factor: 5.482

8.  Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival.

Authors:  Martin C Chang; Nicole S Nevadunsky; Akila N Viswanathan; Christopher P Crum; Colleen M Feltmate
Journal:  Int J Gynecol Pathol       Date:  2010-01       Impact factor: 2.762

Review 9.  Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and meta-analysis.

Authors:  Jing Chen; Rui Wang; Bo Zhang; Xingguang Lin; Juncheng Wei; Yao Jia; Ye Yin; Shuangmei Ye; Tao Zhu; Gang Chen; Yongxun Yuan; Weiguo Lu; Kezhen Li
Journal:  Am J Obstet Gynecol       Date:  2016-04-29       Impact factor: 8.661

10.  The problem of late ovarian metastases from primary cervical adenocarcinoma.

Authors:  Katie A Ashton; James Scurry; Sepehr N Tabrizi; Suzanne M Garland; Geoffrey Otton; Nikola A Bowden
Journal:  Gynecol Oncol Rep       Date:  2015-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.